Replica Allows Clinicians to Remotely Monitor Patients from Anywhere
in Real Time
LAS VEGAS--(BUSINESS WIRE)--Mar. 6, 2018--
Today at the 2018 HIMSS Annual Conference,Masimo (NASDAQ:
MASI) announced the release of Replica™, an application for smart phones
and tablets that works in conjunction with Masimo Patient SafetyNet™*, a
supplemental remote monitoring and clinician notification system.
Replica allows clinicians to view continuous monitoring data for
multiple patients, as well as view and respond to alarms and alerts, all
from their smart phones, regardless of location.
This press release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20180306005740/en/
Masimo Replica™ (Photo: Business Wire)
With Patient SafetyNet, continuous monitoring data are available at a
central viewing station. Replica builds on this capability by delivering
continuous monitoring data and intelligent alarm notifications to remote
clinicians on smart phones. Replica displays data relayed from connected
bedside Masimo and third-party devices, such as ventilators and patient
monitors. Replica also allows the display of high fidelity data, such as
waveforms, in real time. Clinicians can also access up to 96 hours of
historical data, aiding assessment of potential deterioration over time.
The collation of data from multiple disparate sources in a single
location provides clinicians with a more complete picture of patient
status at a glance.
Replica features intelligent two-way alarm and alert notification
technology, derived from Patient SafetyNet’s existing capabilities, that
offers significant advantages over systems which send out rudimentary,
one-way notifications. Replica extends Patient SafetyNet’s intelligence
by routing and escalating detailed, color-coded alarm and alert
notifications to active mobile devices, reaching on-duty and available
clinicians. Clinicians can respond to notifications from the app –
choosing to accept or forward – and see if other clinicians have already
responded. By combining detailed monitoring data with intelligent
notification, Replica helps to improve clinical collaboration, promoting
informed, timely response and effective clinical coordination.
Joe Kiani, Founder and CEO of Masimo, said, “Given the high
patient-to-clinician ratios common in many areas, such as the
medical-surgical floor, there is an increasing need for continuous
remote visibility into patient status. Patient SafetyNet, combined with
the power of SET® pulse oximetry, has been shown to save
lives, reduce rapid response activations, and reduce costs in
post-surgical wards.1-3 Replica takes the benefits of Patient
SafetyNet to a new level by intelligently and reliably delivering
valuable patient data and notifications to clinicians wherever they may
be – thus helping them to respond and intervene as effectively and
efficiently as possible.”
@MasimoInnovates |
#Masimo
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
References
1. Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
Events and Intensive Care Unit Transfers: A Before-And-After Concurrence
Study. Anesthesiology. 2010; 112(2):282-287.
2. Taenzer AH
et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
3.
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™*
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 and is the primary pulse oximetry at 17 of the top 20
hospitals listed in the 2017-18 U.S. News and World Report Best
Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect® (MOC-9®) interface, enabling
other companies to augment Root with new features and measurement
capabilities. Masimo is also taking an active leadership role in mHealth
with products such as the Radius-7® wearable patient monitor,
iSpO2® pulse oximeter for smartphones, and the
MightySat™ fingertip pulse oximeter. Additional information about Masimo
and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
ORi has not received FDA 510(k) clearance and is not available for sale
in the United States.
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
References
4. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
5.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
6. Taenzer AH et al. Impact of Pulse Oximetry Surveillance
on Rescue Events and Intensive Care Unit Transfers: A Before-And-After
Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
7.
Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
8.
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
9.
Estimate: Masimo data on file.
10. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo Replica™ and Patient SafetyNet™. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including Masimo Replica and Patient
SafetyNet, contribute to positive clinical outcomes and patient safety;
risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique advantages; as
well as other factors discussed in the "Risk Factors" section of our
most recent reports filed with the Securities and Exchange Commission
("SEC"), which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180306005740/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com